| Literature DB >> 22957292 |
Valéria Valim1, Roberta Hora Rocha, Roberta Barcelos Couto, Thaysa Simões Paixão, Erica Vieira Serrano.
Abstract
Acute fibrinous and organizing pneumonia (AFOP), recently described, is a histologic pattern characterized by the presence of fibrin "balls" within alveolar spaces. The term undifferentiated connective tissue disease (UCTD) is used to identify autoimmune systemic diseases that do not fulfill the criteria to be classified as a definitive connective tissue disease. The AFOP has never been reported in association with UCTD. The present reported case is a 39-year-old Caucasian, female with dry cough and progressive dyspnea. Eight months later, she was diagnosed with "organizing pneumonia" based on clinical history and radiologic images. She manifested Raynaud's Phenomenon, sicca syndrome, boot and gloves neuropathic pain, and previous hypothyroidism. Antinuclear antibody, rheumatoid factor, and specific autoantibodies were negative. Salivary gland biopsy and electroneuromyiography were normal. The capillaroscopy showed a "scleroderma" pattern with capillary deletion and ectasia. She experienced clinical and radiologic worsening. Despite being submitted to cyclophosphamide pulse, she developed hemorrhage and then died. Thoracotomy pulmonary specimen showed histological pattern of AFOP. This paper shows a rare association of AFOP with UCTD.Entities:
Year: 2012 PMID: 22957292 PMCID: PMC3420729 DOI: 10.1155/2012/549298
Source DB: PubMed Journal: Case Rep Rheumatol ISSN: 2090-6897
Figure 1(a) and (b) CT findings of “focal areas of lung parenchymal infiltrates with ground-glass opacities, associated (white arrow) with septal thickening (yellow arrow), with peripheral distribution.” (c) and (d) CT findings of interstitial infiltrate, with diffuse ground glass opacity with foci of parenchymal densification (yellow arrow) and some air bronchograms (white arrow). (e) Histhopatological examination showing (1) intra-alveolar accumulation of fibrin in the form of solid blocks; (2) acute inflammatory infiltrate in the interstitium; (3) alveolar septal edema and congestion; (4) xantomatososum macrophages accumulation.
Inflammatory activity tests and serologic and autoantibodies tests.
| 09/12/2007 | 10/30/2007 | 03/06/2008 | 07/02/2008 | |
|---|---|---|---|---|
| ESR (mm/h) | 67 | 54 | 55 | |
| CRP (mg/dL) | <0,5 | <0,5 | <0,5 | |
| Total protein (g/dL) | 72 | |||
| ANA | Nonreactive | Nonreactive | Nonreactive | |
| RF (UI/mL) | <40 | <40 | <40 | |
| P-ANCA | 1 : 20 | |||
| Anti-TPO (UI/mL) | 842 | |||
| Anti-TBG (UI/mL) | 141 | |||
|
| ||||
| Negative autoantibodies: anti-Scl70, anti-Jo1, c-ANCA, anti-RNP, anti-SS-A, anti-SS-B, anti-CCP, antinative DNA, and anticentromere. | ||||
|
| ||||
|
| ||||
ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; ANA: antinuclear antibodies; RF: rheumatoid factor; P-ANCA: perinuclear antineutrophil cytoplasmic antibodies; anti-TPO: antithyroid peroxidase; anti-TGB: antithyroxine binding globulin; anti-Scl 70: antitopoisomerase antibodies; anti-Jo 1: antisynthetase antibodies; c-ANCA: cytoplasmic antineutrophil cytoplasmic antibodies; anti-RNP: antiribonucleoproteins antitopoisomerase antibodies; anti-SS-A: anti-Sjogren's Syndrome antigen A; anti-SS-B: anti-Sjogren's syndrome antigen B; anti-CCP: anticitrulline containing peptide; HBV: hepatitis B virus; HCV: hepatitis C virus; RV: reference value.
Figure 2Panoramic nailfold capillaroscopy of the left and right fourth digits showing a scleroderma standard microangiopathy: dilated capillaries and devascularization areas.
Described cases of acute fibrinous organizing pneumonia, 2002–2011.
| Rheumatologic disease | Age | Sex | Treatment | Time | Outcome evolution | Author, year |
|---|---|---|---|---|---|---|
| Ankylosing spondylitis | 55 | M | Corticoid | — | Survived | Beasley et al., 2002, [ |
| Polymyositis | 78 | F | Corticoid | — | Death | Beasley et al., 2002, [ |
| Fibromyalgia | 58 | F | Antibiotic | — | Survived | Beasley et al., 2002, [ |
| Juvenile dermatomyositis | 14 | F | Azithromycin, immunoglobulin, cyclophosphamide, methylprednisolone, and cyclosporine | 2 months | Death | Prahalad et al., 2005, [ |
| Stigma of rheumatic disease | 47 | M | Prednisone | 3 months | Survived | Balduin et al., 2007, [ |
| SLE and APS | 16 | M | Prednisone, cyclophosphamide, anticoagulants | 2,5 months | Survived | Hariri et al., 2010, [ |
SLE: systemic erythematosus lupus; APS: antiphospholipid syndrome.